Nivolumab plus ipilimumab with or without live bacterial supplementation in metastatic renal cell carcinoma: a randomized phase 1 trial
出版年份 2022 全文链接
标题
Nivolumab plus ipilimumab with or without live bacterial supplementation in metastatic renal cell carcinoma: a randomized phase 1 trial
作者
关键词
-
出版物
NATURE MEDICINE
Volume 28, Issue 4, Pages 704-712
出版商
Springer Science and Business Media LLC
发表日期
2022-03-01
DOI
10.1038/s41591-022-01694-6
参考文献
相关参考文献
注意：仅列出部分参考文献，下载原文获取全部文献信息。- Evaluation of Clear Cell, Papillary, and Chromophobe Renal Cell Carcinoma Metastasis Sites and Association With Survival
- (2021) Shaan Dudani et al. JAMA Network Open
- Integrating taxonomic, functional, and strain-level profiling of diverse microbial communities with bioBakery 3
- (2021) Francesco Beghini et al. eLife
- Gut microbiota signatures are associated with toxicity to combined CTLA-4 and PD-1 blockade
- (2021) Miles C. Andrews et al. NATURE MEDICINE
- Microbiota-Centered Interventions: The Next Breakthrough in Immuno-Oncology?
- (2021) Lisa Derosa et al. Cancer Discovery
- Dietary cholesterol drives fatty liver-associated liver cancer by modulating gut microbiota and metabolites
- (2020) Xiang Zhang et al. GUT
- Association of Probiotic Clostridium butyricum Therapy with Survival and Response to Immune Checkpoint Blockade in Patients with Lung Cancer
- (2020) Yusuke Tomita et al. Cancer Immunology Research
- 696O_PR Nivolumab + cabozantinib vs sunitinib in first-line treatment for advanced renal cell carcinoma: First results from the randomized phase III CheckMate 9ER trial
- (2020) T.K. Choueiri et al. ANNALS OF ONCOLOGY
- Conserved Interferon-γ Signaling Drives Clinical Response to Immune Checkpoint Blockade Therapy in Melanoma
- (2020) Catherine S. Grasso et al. CANCER CELL
- Stool Microbiome Profiling of Patients with Metastatic Renal Cell Carcinoma Receiving Anti–PD-1 Immune Checkpoint Inhibitors
- (2020) Nicholas J. Salgia et al. EUROPEAN UROLOGY
- Fecal microbiota transplant promotes response in immunotherapy-refractory melanoma patients
- (2020) Erez N. Baruch et al. SCIENCE
- Avelumab plus Axitinib versus Sunitinib for Advanced Renal-Cell Carcinoma
- (2019) Robert J. Motzer et al. NEW ENGLAND JOURNAL OF MEDICINE
- Pembrolizumab plus Axitinib versus Sunitinib for Advanced Renal-Cell Carcinoma
- (2019) Brian I. Rini et al. NEW ENGLAND JOURNAL OF MEDICINE
- Renal cell carcinoma: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up
- (2019) Bernard Escudier et al. ANNALS OF ONCOLOGY
- NCCN Guidelines Insights: Kidney Cancer, Version 2.2020
- (2019) Robert J. Motzer et al. Journal of the National Comprehensive Cancer Network
- Nivolumab plus ipilimumab versus sunitinib in first-line treatment for advanced renal cell carcinoma: extended follow-up of efficacy and safety results from a randomised, controlled, phase 3 trial
- (2019) Robert J Motzer et al. LANCET ONCOLOGY
- Drug-Resistant E. coli Bacteremia Transmitted by Fecal Microbiota Transplant
- (2019) Zachariah DeFilipp et al. NEW ENGLAND JOURNAL OF MEDICINE
- Negative association of antibiotics on clinical activity of immune checkpoint inhibitors in patients with advanced renal cell and non-small-cell lung cancer
- (2018) L Derosa et al. ANNALS OF ONCOLOGY
- Gut microbiota modulate T cell trafficking into human colorectal cancer
- (2018) Eleonora Cremonesi et al. GUT
- Nivolumab plus Ipilimumab versus Sunitinib in Advanced Renal-Cell Carcinoma
- (2018) Robert J. Motzer et al. NEW ENGLAND JOURNAL OF MEDICINE
- The commensal microbiome is associated with anti–PD-1 efficacy in metastatic melanoma patients
- (2018) Vyara Matson et al. SCIENCE
- Abstract 4987: Biofilm-producing sulfate-reducing bacteria suppress tumor burden in a rat model of colon cancer
- (2018) Susheel Bhanu Busi et al. CANCER RESEARCH
- Pembrolizumab monotherapy for previously treated metastatic triple-negative breast cancer: cohort A of the phase II KEYNOTE-086 study
- (2018) S Adams et al. ANNALS OF ONCOLOGY
- Specific substrate-driven changes in human faecal microbiota composition contrast with functional redundancy in short-chain fatty acid production
- (2017) Nicole Reichardt et al. ISME Journal
- Gut microbiome modulates response to anti–PD-1 immunotherapy in melanoma patients
- (2017) V. Gopalakrishnan et al. SCIENCE
- Gut microbiome influences efficacy of PD-1–based immunotherapy against epithelial tumors
- (2017) Bertrand Routy et al. SCIENCE
- Immunomodulatory Activity of Nivolumab in Metastatic Renal Cell Carcinoma
- (2016) Toni K. Choueiri et al. CLINICAL CANCER RESEARCH
- Formation of propionate and butyrate by the human colonic microbiota
- (2016) Petra Louis et al. ENVIRONMENTAL MICROBIOLOGY
- Safety assessment of the Clostridium butyricum MIYAIRI 588® probiotic strain including evaluation of antimicrobial sensitivity and presence of Clostridium toxin genes in vitro and teratogenicity in vivo
- (2016) K Isa et al. HUMAN & EXPERIMENTAL TOXICOLOGY
- Fecal Microbiota Transplantation Induces Remission in Patients With Active Ulcerative Colitis in a Randomized Controlled Trial
- (2015) Paul Moayyedi et al. GASTROENTEROLOGY
- Findings From a Randomized Controlled Trial of Fecal Transplantation for Patients With Ulcerative Colitis
- (2015) Noortje G. Rossen et al. GASTROENTEROLOGY
- Commensal Bifidobacterium promotes antitumor immunity and facilitates anti-PD-L1 efficacy
- (2015) A. Sivan et al. SCIENCE
- Trimmomatic: a flexible trimmer for Illumina sequence data
- (2014) Anthony M. Bolger et al. BIOINFORMATICS
- Duodenal Infusion of Donor Feces for Recurrent Clostridium difficile
- (2013) Els van Nood et al. NEW ENGLAND JOURNAL OF MEDICINE
- FungiQuant: A broad-coverage fungal quantitative real-time PCR assay
- (2012) Cindy M Liu et al. BMC MICROBIOLOGY
- BactQuant: An enhanced broad-coverage bacterial quantitative real-time PCR assay
- (2012) Cindy M Liu et al. BMC MICROBIOLOGY
Discover Peeref hubs
Discuss science. Find collaborators. Network.
Join a conversationCreate your own webinar
Interested in hosting your own webinar? Check the schedule and propose your idea to the Peeref Content Team.
Create Now